NEW ZEALAND DATA SHEET

1. PRODUCT NAME

VFEND® 50 mg, 200 mg film coated Tablets.
VFEND® 40 mg/mL Powder for Oral Suspension.
VFEND® 200 mg Powder for Infusion.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Film-coated Tablets

Each tablets contain 50 mg or 200 mg of voriconazole.

Excipient(s) with known effect
Each tablet contains 63.42 mg or 253.675 mg lactose monohydrate. For the full list of excipients, see Section 6.1 List of excipients.

Powder for Oral Suspension

Each bottle contains 45 g of Powder for Oral Suspension. Following reconstitution, the volume of suspension is 75 mL, providing a usable volume of 70 mL of suspension at a voriconazole concentration of 40 mg/mL.

Excipient(s) with known effect
Each ml of suspension contains 0.54 g sucrose. For the full list of excipients, see Section 6.1 List of excipients.

Powder for Infusion

Each vial contains 200 mg voriconazole. The lyophilised powder contents of the vials are intended for reconstitution with 19 mL Water for Injections to produce a solution containing 10 mg/mL voriconazole and 160 mg/mL of sulfobutyl betadex sodium (SBECD). The resulting solution is further diluted prior to administration as an intravenous infusion (see Section 4.2 Dose and method of administration)

Excipient(s) with known effect
Each vial contains 217.6 mg sodium. For the full list of excipients, see Section 6.1 List of excipients.
3. PHARMACEUTICAL FORM

Vfend 50 mg film-coated Tablets are white, round tablets, debossed “Pfizer” on one side and “VOR50” on the reverse.

Vfend 200 mg film-coated Tablets are white, capsule-shaped tablets, debossed “Pfizer” on one side and “VOR200” on the reverse.

Vfend Powder for Oral Suspension is a white to off-white powder providing a white to off-white, orange flavoured suspension when reconstituted.

Vfend Powder for Infusion is a white to off white powder.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Vfend is indicated for treatment of the following fungal infections:

- Invasive aspergillosis.
- Serious Candida infections (including C. krusei), including oesophageal and systemic Candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).
- Serious fungal infections caused by Scedosporium spp. and Fusarium spp.
- Other serious fungal infections, in patients intolerant of, or refractory to, other therapy.

4.2 Dose and method of administration

Dose

Therapy must be initiated with the specified loading dose regimen of either intravenous or oral voriconazole to achieve plasma concentrations on Day 1 that are close to steady state. On the basis of the high oral bioavailability (96%; see Section 5.2 Pharmacokinetic properties) switching between intravenous and oral administration is appropriate when clinically indicated.

Intravenous administration is not recommended for the treatment of oesophageal candidiasis; dosage recommendations for oesophageal candidiasis are provided in the following table.

| Detailed information on dosage recommendations for oesophageal candidiasis |
|------------------|-----------------|------------------|
|                   | Intravenous     | Oral             |
|                   | Patients 40 kg or above | Patients less than 40 kg |
| Serious invasive Candida infections | | |
| Loading dose regimen (first 24 hours) | 6 mg/kg every 12 hours (for the first 24 hours) | 400 mg or 10 mL every 12 hours (for the first 24 hours) |
| Maintenance dose (after first 24 hours) | 3 mg/kg every 12 hours | 200 mg or 5 mL twice daily |
| Oesophageal candidiasis | 200 mg or 5 mL every 12 hours (for the first 24 hours) | 100 mg or 2.5 mL twice daily |
Loading dose regimen (first 24 hours) | Not recommended | 400 mg or 10 mL every 12 hours (for the first 24 hours) 200 mg or 5 mL twice daily | 200 mg or 5 mL every 12 hours (for the first 24 hours) 100 mg or 2.5 mL twice daily
Maintenance dose (after first 24 hours) | Not recommended | 200 mg or 5 mL twice daily | 100 mg or 2.5 mL twice daily

**Invasive Aspergillosis/Scedosporium and Fusarium infections/other serious fungal infections**

| Loading dose regimen (first 24 hours) | 6 mg/kg every 12 hours (for the first 24 hours) | 400 mg or 10 mL every 12 hours (for the first 24 hours) 200 mg or 5 mL twice daily | 200 mg or 5 mL every 12 hours (for the first 24 hours) 100 mg or 2.5 mL twice daily

* The oral suspension formulation has not been assessed for efficacy or safety in children; however, bioequivalence with the tablet in healthy adults has been shown.

**Intravenous administration**

If patient response at 3 mg/kg every 12 hours is inadequate, the intravenous maintenance dose may be increased to 4 mg/kg every 12 hours.

If patients are unable to tolerate 4 mg/kg every 12 hours, reduce the intravenous dose to 3 mg/kg every 12 hours.

Phenytoin may be co-administered with voriconazole if the maintenance dose of voriconazole is increased to 5 mg/kg intravenously every 12 hours. The loading dose regimen remains unchanged (see Section 4.4 Special warnings and precautions for use and Section 4.5 Interactions with medicines and other forms of interactions).

The dose recommendation for concomitant use of intravenous voriconazole and oral efavirenz has not been determined (see Section 4.5 Interactions with medicines and other forms of interactions).

Treatment duration depends upon patients’ clinical and mycological response.

**Oral administration**

If patient response is inadequate, the maintenance dose may be increased to 300 mg twice daily for oral administration. For patients less than 40 kg the oral dose may be increased to 150 mg twice daily. If patients are unable to tolerate treatment at these higher doses reduce the oral dose by 50 mg steps to a minimum 200 mg twice daily (or 100 mg twice daily for patients less than 40 kg) maintenance dose.

Phenytoin may be co-administered with voriconazole if the maintenance dose of voriconazole is increased from 200 mg to 400 mg twice daily orally (100 mg to 200 mg twice daily orally in patients less than 40 kg). The loading dose regimen remains unchanged (see Section 4.4 Special warnings and precautions for use and Section 4.5 Interactions with medicines and other forms of interaction).

When voriconazole is co-administered with efavirenz, the voriconazole maintenance dose should be increased to 400 mg every 12 hours and the efavirenz dose should be decreased to 300 mg every 24 hours (see Section 4.2 Contraindications and Section 4.5 Interactions with medicines and other forms of interaction).
Treatment duration depends upon patients’ clinical and mycological response.

Dosage adjustments

Elderly
No dose adjustment is necessary for elderly patients.

Renal impairment
The pharmacokinetics of orally administered voriconazole are not affected by renal impairment. Therefore, no adjustment is necessary for oral dosing for patients with mild to severe renal impairment.

In patients with moderate to severe renal dysfunction (creatinine clearance <50 mL/min), including dialysis patients, accumulation of the intravenous vehicle, SBECV, occurs. Oral voriconazole should be administered to these patients, unless an assessment of the risk-benefit to the patient justifies the use of intravenous voriconazole. Serum creatinine levels should be closely monitored in these patients and, if increases occur, consideration should be given to changing to oral voriconazole therapy (see Section 5.2 Pharmacokinetic properties, Renal Impairment).

Hepatic impairment
No dose adjustment is necessary in patients with acute hepatic injury, manifested by elevated liver function tests (ALT, AST) (but continued monitoring of liver function tests for further elevations is recommended).

It is recommended that the standard loading dose regimens be used but that the maintenance dose be halved in patients with mild to moderate hepatic cirrhosis (Child-Pugh A and B) receiving voriconazole.

Voriconazole has not been studied in patients with severe chronic hepatic cirrhosis (Child-Pugh C). Voriconazole has been associated with elevations in liver function tests and clinical signs of liver damage such as jaundice, and must only be used in patients with severe hepatic impairment if the benefit outweighs the potential risk. Patients with severe hepatic impairment must be carefully monitored for drug toxicity (see Section 4.8 Undesirable effects).

Paediatric population
Safety and efficacy in paediatric subjects below the age of 2 years has not been established (see Section 5.2 Pharmacokinetic properties). Therefore, voriconazole is not recommended for children less than 2 years of age.

The recommended maintenance dosing regimen in paediatric patients 2 to < 12 years is as follows

<table>
<thead>
<tr>
<th>Loading dose regimen</th>
<th>No oral or intravenous loading dose is recommended</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maintenance dose</td>
<td>Intravenous dose*</td>
</tr>
<tr>
<td></td>
<td>7 mg/kg twice daily</td>
</tr>
</tbody>
</table>

* Based on a population pharmacokinetic analysis in 82 immunocompromised patients aged 2 to < 12 years

** Based on a population pharmacokinetic analysis in 47 immunocompromised patients aged 2 to < 12 years
If paediatric patients are unable to tolerate an intravenous dose of 7 mg/kg twice daily, a dose reduction from 7 mg/kg to 4 mg/kg twice daily may be considered based on the population pharmacokinetic analysis and previous clinical experience. This provides equivalent exposure to 3 mg/kg twice daily in adults (see dosage regimen under the heading Adults in this section).

Use in paediatric patients aged 2 to < 12 years with hepatic or renal insufficiency has not been studied (see Section 4.8 Undesirable effects and Section 5.2 Pharmacokinetic properties).

These paediatric dose recommendations are based on studies in which Vfend was administered as the Powder for Oral Suspension formulation. Bioequivalence between the Powder for Oral Suspension and the Tablets have not been investigated in a paediatric population. Considering the assumed limited gastro-enteric transit time in pediatrics, the absorption of tablets may be different in paediatric compared to adult patients.

Adolescents (12 -16 years of age) should be dosed as adults.

**Method of administration**

**Oral administration**

Vfend film-coated Tablets are administered orally at least one hour before, or one hour following, a meal.

Vfend powder oral suspension is administered orally at least one hour before, or two hours following, a meal. The Powder for Oral Suspension should be reconstituted and administered using the syringe provided in the pack. For reconstitution instructions, see Section 6.6 Special precautions for disposal and other handling)

**Intravenous administration**

Vfend powder for infusion requires reconstitution and dilution (see section 6.6 Special precautions for disposal and other handling) prior to administration as an intravenous infusion. Vfend powder for infusion is not recommended for bolus injection.

It is recommended that Vfend powder for infusion to be administered at a maximum rate of 3 mg/kg per hour over 1 to 2 hours. Electrolyte disturbances such as hypokalaemia, hypomagnesaemia and hypocalcaemia should be corrected prior to initiation of voriconazole therapy (see Section 4.4 Special warnings and precautions for use, Cardiovascular).

**4.3 Contraindications**

Vfend is contraindicated in patients with known hypersensitivity to voriconazole or to any of the excipients listed in Section 6.1 List of excipients.

Co-administration of the CYP3A4 substrates, pimozide or quinidine with voriconazole is contraindicated since increased plasma concentrations of these medicinal products can lead to QTc prolongation and rare occurrences of *torsades de pointes* (see Section 4.5 Interactions with other medicines and other forms of interactions).

Co-administration of voriconazole with rifabutin, rifampicin, carbamazepine and long-acting barbiturates (e.g., phenobarbitone) is contraindicated since these medicinal products are likely to decrease plasma voriconazole concentrations significantly (see Section 4.5 Interactions with other medicines and other forms of interactions).
Co-administration of standard doses of voriconazole with patients receiving efavirenz doses of 400 mg once daily or higher is contraindicated, because efavirenz significantly decreases plasma voriconazole concentrations in healthy subjects at these doses. Voriconazole also significantly increases efavirenz plasma concentrations (see Section 4.5 Interactions with other medicines and other forms of interactions). For information pertaining to lower doses of efavirenz, see Section 4.2 Dose and method of administration and Section 4.5 Interactions with other medicines and other forms of interactions.

Co-administration of ergot alkaloids (ergotamine, dihydroergotamine), which are CYP3A4 substrates, is contraindicated since increased plasma concentrations of these medicinal products can lead to ergotism (see Section 4.5 Interactions with other medicines and other forms of interactions).

Co-administration of voriconazole and sirolimus is contraindicated, since voriconazole is likely to increase plasma concentrations of sirolimus significantly (see Section 4.5 Interactions with other medicines and other forms of interactions).

Co-administration of voriconazole with patients receiving high doses of ritonavir (400 mg and higher twice daily) is contraindicated, because ritonavir significantly decreases plasma voriconazole concentrations in healthy subjects at these doses (see Section 4.5 Interactions with other medicines and other forms of interactions). For information pertaining to lower doses of ritonavir, see Section 4.4 Special warnings and precautions for use.

Co-administration of voriconazole with St John’s Wort is contraindicated (see Section 4.5 Interactions with other medicines and other forms of interactions).

4.4 Special warnings and precautions for use

Hypersensitivity

Caution should be used in prescribing voriconazole to patients with hypersensitivity to other azoles.

Cardiovascular

Some azoles, including voriconazole have been associated with QT interval prolongation. There have been rare cases of *torsades de pointes* in patients taking voriconazole who had risk factors, such as history of cardiotoxic chemotherapy, cardiomyopathy, hypokalemia and concomitant medications that may have been contributory. Voriconazole should be administered with caution to patients with potentially proarrhythmic conditions, such as,

- Congenital or acquired QT-prolongation
- Cardiomyopathy, in particular when heart failure is present
- Sinus bradycardia
- Existing symptomatic arrhythmias
- Concomitant medicinal product that is known to prolong QT interval (see Section 4.5 Interactions with other medicines and other forms of interactions).

Electrolyte disturbances such as hypokalaemia, hypomagnesaemia and hypocalcaemia should be monitored and corrected, if necessary, prior to initiation of and during voriconazole therapy (see Section 4.2 Dose and method of administration).
Infusion-related reactions

Anaphylactoid-type reactions, including flushing, fever, sweating, tachycardia, chest tightness, dyspnoea, faintness, nausea, pruritus and rash have been observed during administration of the intravenous formulation of voriconazole. Depending on the severity of symptoms, consideration should be given to stopping treatment.

Hepatic toxicity

In clinical trials, there have been cases of serious hepatic reactions during treatment with voriconazole (including clinical hepatitis, cholestasis and fulminant hepatic failure including fatalities). Instances of hepatic reactions were noted to occur primarily in patients with serious underlying medical conditions (predominantly haematological malignancy). Transient hepatic reactions, including hepatitis and jaundice, have occurred among patients with no other identifiable risk factors. Liver dysfunction has usually been reversible on discontinuation of therapy.

Patients receiving voriconazole must be carefully monitored for hepatic toxicity. Clinical management should include laboratory evaluation of hepatic function (specifically AST and ALT) at the initiation of treatment with voriconazole and at least weekly for the first month of treatment. If treatment is continued, monitoring frequency can be reduced to monthly if there are no changes in the liver function tests.

If the liver function tests become markedly elevated, voriconazole should be discontinued, unless the medical judgment of the risk-benefit of the treatment for the patient justifies continued use (see Section 4.2 Dose and method of administration).

Renal

The pharmacokinetic parameters of orally administered voriconazole are not affected by renal impairment. However, acute renal failure has been observed in severely ill patients undergoing treatment with voriconazole. Patients being treated with voriconazole are likely to be treated concomitantly with nephrotoxic medications and have concurrent conditions that may result in decreased renal function.

In patients with moderate to severe renal dysfunction (creatinine clearance <50 mL/min), including dialysis patients, accumulation of the intravenous vehicle SBECD occurs. Oral voriconazole should be administered to these patients, unless an assessment of the risk to the patient justifies the use of intravenous voriconazole.

Patients should be monitored for the development of abnormal renal function. This should include laboratory evaluation, particularly serum creatinine.

Monitoring of pancreatic function

Adults and children with risk factors for acute pancreatitis (e.g., recent chemotherapy, haematopoietic stem cell transplantation (HSCT)), should be monitored closely during Vfend treatment. Monitoring of serum amylase or lipase may be considered in this clinical situation.

Dermatological adverse events

Severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS), which can be life-threatening or fatal, have been reported with the use of
voriconazole. If a patient develops a suspected SCAR, voriconazole should be discontinued immediately and an alternative treatment should be considered.

In addition, voriconazole has been associated with photosensitivity skin reaction. It is recommended that patients, including children, avoid exposure to direct sunlight during voriconazole treatment and use measures such as protective clothing and sunscreen with high sun protection factor (SPF) (see Squamous cell carcinoma in this section).

The frequency of phototoxicity reactions is higher in the paediatric population. As an evolution towards SCC has been reported, stringent measures for the photo-protection are warranted in this population of patients. In children experiencing photo-aging injuries such as lentigines or ephelides, sun avoidance and dermatologic follow-up are recommended even after treatment discontinuation.

**Long-term treatment**

The following severe adverse events have been reported in relation with long-term voriconazole treatment:

**Squamous cell carcinoma (SCC)**

In patients with photosensitivity skin reactions and additional risk factors, squamous cell carcinoma of the skin and melanoma have been reported during long-term therapy. If phototoxic reactions occur, multidisciplinary advice should be sought and the patient should be referred to a dermatologist. Voriconazole discontinuation should be considered. Dermatologic evaluation should be performed on a systematic and regular basis, whenever voriconazole is continued despite the occurrence of phototoxicity-related lesions, to allow early detection and management of premalignant lesions. If a patient develops a skin lesion consistent with premalignant skin lesions, squamous cell carcinoma or melanoma, voriconazole discontinuation should be considered.

**Non-infectious periostitis**

Periostitis has been reported in transplant patients during long-term voriconazole therapy. If a patient develops skeletal pain and radiologic findings compatible with periostitis, voriconazole should be discontinued.

**Visual adverse events**

There have been post-marketing reports of prolonged visual adverse events, including optic neuritis and papilloedema. These events occurred primarily in severely ill patients who had underlying conditions and/or concomitant medications which may have caused or contributed to these events (see Section 4.8 Undesirable effects, Visual disturbances).

**Everolimus (CYP3A4 substrate, P-gp substrate)**

Co-administration of voriconazole with everolimus is not recommended because voriconazole is expected to significantly increase everolimus concentrations. Currently there are insufficient data to allow dosing recommendations in this situation (see Section 4.5 Interactions with other medicines and other forms of interactions).
Fluconazole (CYP2C9, CYP2C19 and CYP3A4 inhibitor)

Co-administration of oral voriconazole and oral fluconazole resulted in significant increase in Cmax and AUCτ of voriconazole in healthy subjects. The reduced dose and/or frequency of voriconazole and fluconazole that would reduce this effect have not been established. Monitoring for voriconazole associated adverse events is recommended if voriconazole is used sequentially after fluconazole (see Section 4.5 Interactions with other medicines and other forms of interactions).

Phenytoin (CYP2C9 substrate and potent CYP450 inducer)

Careful monitoring of phenytoin levels is recommended when phenytoin is co-administered with voriconazole. Concomitant use of voriconazole and phenytoin should be avoided unless the benefit outweighs the risk (see Section 4.5 Interactions with other medicines and other forms of interactions).

Ritonavir (potent CYP450 inducer: CYP3A4 inhibitor and substrate)

Co-administration of voriconazole and low dose ritonavir (100 mg twice daily) should be avoided unless an assessment of the benefit/risk justifies the use of voriconazole (see Section 4.5 Interactions with other medicines and other forms of interactions). Co-administration of voriconazole and ritonavir 400 mg and higher twice daily is contraindicated (see Section 4.3 Contraindications).

Methadone (CYP3A4 substrate)

Increased plasma concentrations of methadone have been associated with toxicity including QT prolongation. Frequent monitoring for adverse events and toxicity related to methadone is recommended during co-administration. Dose reduction of methadone may be needed (see Section 4.5 Interactions with other medicines and other forms of interactions).

Short acting opiates (CYP3A4 substrate)

Reduction in the dose of alfentanil, fentanyl and other short acting opiates similar in structure to alfentanil and metabolised by CYP3A4 (e.g., sufentanil) should be considered when co-administered with voriconazole (see Section 4.5 Interactions with other medicines and other forms of interactions). As the half-life of alfentanil is prolonged in a 4-fold manner when alfentanil is co-administered with voriconazole and in an independent published study, concomitant use of voriconazole with fentanyl resulted in an increase in the mean AUC 0-∞ of fentanyl by 1.4-fold, frequent monitoring for opiate-associated adverse events (including a longer respiratory monitoring period) may be necessary.

Long acting opiates (CYP3A4 substrate)

Reduction in the dose of oxycodone and other long-acting opiates metabolised by CYP3A4 (e.g., hydrocodone) should be considered when co-administered with voriconazole. Frequent monitoring for opiate-associated adverse events may be necessary (see Section 4.5 Interactions with other medicines and other forms of interactions).

Advice about lactose and sucrose

Vfend Tablets contain lactose and should not be given to patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
Vfend Powder for Oral Suspension contains sucrose (0.54 g/mL) and should not be given to patients with rare hereditary problems of fructose intolerance, sucrase-isomaltase deficiency or glucose-galactose malabsorption.

Sodium content
Each vial of Vfend Powder for Infusion contains 217.6 mg of sodium. This should be taken into consideration for patients on a controlled sodium diet.

Paediatric population
Safety and efficacy in paediatric subjects below the age of two years has not been established (see section 5.2 Clinical safety and efficacy). A higher frequency of liver enzyme elevations was observed in the paediatric population (see section 4.8 Undesirable effects). Hepatic function and pancreatic function should be monitored. Oral bioavailability may be limited in paediatric patients 2 to 12 years with malabsorption and very low body weight for age. In that case, intravenous voriconazole administration is recommended.

4.5 Interaction with other medicines and other forms of interaction
Unless otherwise specified, drug interaction studies have been performed in healthy male subjects using multiple dosing to steady state with oral voriconazole at 200 mg twice daily. These results are relevant to other populations and routes of administration.

This section addresses the effects of other medicinal products on voriconazole, the effects of voriconazole on other medicinal products and two-way interactions. The interactions for the first two sections are presented in the following order: contraindications, those requiring dosage adjustment, those requiring careful clinical and/or biochemical monitoring and finally those that have no significant pharmacokinetic interaction but may be of clinical interest in this therapeutic field.

Effects of other medicinal products on voriconazole
Voriconazole is metabolised by cytochrome P450 isoenzymes, CYP2C19, CYP2C9 and CYP3A4. Inhibitors or inducers of these isoenzymes may increase or decrease voriconazole plasma concentrations, respectively.

The exposure to voriconazole is significantly reduced by the concomitant administration of the following agents

**Rifampicin (CYP450 inducer)**
Rifampicin (600 mg once daily) decreased the Cmax (maximum plasma concentration) and AUCτ (area under the plasma concentration time curve within a dose interval) of voriconazole by 93% and 96%, respectively. Co-administration of voriconazole and rifampicin is contraindicated (see Section 4.3 Contraindications).

**Rifabutin (potent CYP450 inducer)**
Rifabutin (300 mg once daily) decreased the Cmax and AUCτ of voriconazole at 200 mg twice daily by 69% and 78%, respectively. During co-administration with rifabutin, the Cmax and AUCτ of voriconazole at 350 mg twice daily were 96% and 68% of the levels when administered alone at 200 mg twice daily. At a voriconazole dose of 400 mg twice daily Cmax
and AUC$_\tau$ were 104% and 87% higher, respectively, compared with voriconazole alone at 200 mg twice daily. Voriconazole at 400 mg twice daily increased Cmax and AUC$_\tau$ of rifabutin by 195% and 331%, respectively. Co-administration of voriconazole with rifabutin is contraindicated (see Section 4.3 Contraindications).

**Ritonavir (potent CYP450 inducer; CYP3A4 inhibitor and substrate)**

The effect of the co-administration of oral voriconazole (200 mg twice daily) and high dose (400 mg) and low dose (100 mg) oral ritonavir was investigated in two separate studies in healthy volunteers. High doses of ritonavir (400 mg twice daily) decreased the steady state Cmax and AUC$_\tau$ of oral voriconazole by an average of 66% and 82% respectively, whereas low doses of ritonavir (100 mg twice daily) decreased the Cmax and AUC$_\tau$ of oral voriconazole by an average of 24% and 39% respectively. Administration of voriconazole did not have a significant effect on mean Cmax and AUC$_\tau$ of ritonavir in the high dose study, although a minor decrease in steady state Cmax and AUC$_\tau$ of ritonavir with an average of 25% and 13% respectively was observed in the low dose ritonavir interaction study. One outlier subject with raised voriconazole levels was identified in each of the ritonavir interaction studies. Co-administration of voriconazole and high doses of ritonavir (400 mg and higher twice daily) is contraindicated (see Section 4.3 Contraindications). Co-administration of voriconazole and low dose ritonavir (100 mg twice daily) should be avoided unless an assessment of the benefit/risk to the patient justifies the use of voriconazole (see Section 4.4 Special warnings and precautions for use).

**Carbamazepine and phenobarbitone (CYP450 inducers)**

Although not studied, carbamazepine or phenobarbitone are likely to significantly decrease plasma voriconazole levels. Co-administration of voriconazole with carbamazepine and long acting barbiturates are contraindicated (see Section 4.3 Contraindications).

**Significant drug interactions that may require voriconazole dosage adjustment or frequent monitoring of voriconazole related adverse events/toxicity**

**Fluconazole (CYP2C9, CYP2C19 and CYP3A4 inhibitor)**

Co-administration of oral voriconazole and oral fluconazole resulted in significant increase in Cmax and AUC$_\tau$ of voriconazole in healthy subjects. The clinical significance of this drug interaction has not been established and the co-administration of voriconazole and oral fluconazole is not recommended. Monitoring for voriconazole associated adverse events is recommended if voriconazole is used sequentially after fluconazole.

**Minor or no significant pharmacokinetic interactions that require no dosage adjustment**

**Cimetidine (non-specific CYP450 inhibitor and increases gastric pH)**

Cimetidine (400 mg twice daily) increased voriconazole Cmax and AUC$_\tau$ by 18% and 23%, respectively. No dosage adjustment of voriconazole is recommended.

**Ranitidine (increases gastric pH)**

Ranitidine (150 mg twice daily) had no significant effect on voriconazole Cmax and AUC$_\tau$. 
**Macrolide antibiotics**

Erythromycin (CYP3A4 inhibitor; 1 g twice daily) and azithromycin (500 mg once daily) had no significant effect on voriconazole Cmax and AUC\(\tau\).

**Effects of voriconazole on other medicinal products**

Voriconazole inhibits the activity of cytochrome P450 isoenzymes, CYP2C19, CYP2C9 and CYP3A4. Therefore, there is potential for voriconazole to increase the plasma levels of drugs metabolised by these CYP450 isoenzymes.

Voriconazole should be administered with caution in patients receiving concomitant medication that is known to prolong QT interval. When there is also a potential for voriconazole to increase the plasma levels of substances metabolised by CYP3A4 isoenzymes (certain antihistamines, quinidine, pimozide) co-administration is contraindicated (see below and Section 4.3 Contraindications).

**Concomitant use of the following agents with voriconazole is contraindicated**

**Pimozide and quinidine (CYP3A4 substrates)**

Although not studied, co-administration of voriconazole with pimozide or quinidine is contraindicated, since increased plasma concentrations of these drugs can lead to QTc prolongation and rare occurrences of torsades de pointes (see Section 4.3 Contraindications).

**Sirolimus (CYP3A4 substrate)**

Voriconazole increased sirolimus (2 mg single dose) Cmax and AUC\(\tau\) by 556% and 1014%, respectively. Co-administration of voriconazole and sirolimus is contraindicated (see Section 4.3 Contraindications).

**Ergot alkaloids (CYP3A4 substrates)**

Although not studied, voriconazole may increase the plasma concentrations of ergot alkaloids (ergotamine and dihydroergotamine) and lead to ergotism. Co-administration of voriconazole with ergot alkaloids is contraindicated (see Section 4.3 Contraindications).

**St John’s Wort (CYP450 inducer; P-gp inducer)**

In a clinical study in healthy volunteers, St John’s Wort exhibited a short initial inhibitory effect followed by induction of voriconazole metabolism. After 15 days of treatment with St John’s Wort (300 mg three times daily), plasma exposure following a single 400 mg dose of voriconazole decreased by 40-60%. Therefore, concomitant use of voriconazole with St John’s Wort is contraindicated (see Section 4.3 Contraindications).

**Interaction of voriconazole with the following agents may result in increased exposure to these drugs. Careful monitoring and/or dosage adjustment should be considered**

**Cyclosporin (CYP3A4 substrate)**

In stable, renal transplant recipients, voriconazole increased cyclosporin Cmax and AUC\(\tau\) by at least 13% and 70% respectively. When initiating voriconazole in patients already receiving cyclosporin, it is recommended that the cyclosporin dose be halved and cyclosporin level carefully monitored. Increased cyclosporin levels have been associated with nephrotoxicity.
When voriconazole is discontinued, cyclosporin levels must be carefully monitored and the dose increased as necessary.

**Tacrolimus (CYP3A4 substrate)**

Voriconazole increased tacrolimus (0.1 mg/kg single dose) Cmax and AUCτ by 117% and 221%, respectively. When initiating voriconazole in patients already receiving tacrolimus, it is recommended that the tacrolimus dose be reduced to a third of the original dose and tacrolimus levels carefully monitored. Increased tacrolimus levels have been associated with nephrotoxicity. When voriconazole is discontinued, tacrolimus levels must be carefully monitored and the dose increased as necessary.

**Methadone (CYP3A4 substrate)**

Repeat dose administration of oral voriconazole (400 mg every 12 hours for 1 day, then 200 mg every 12 hours for 4 days) increased the Cmax and AUCτ of pharmacologically active R-methadone by 31% (90% CI: 22%, 40%) and 47% (90% CI: 38%, 57%) respectively in subjects receiving a methadone maintenance dose (30-100 mg daily) (see Section 4.4 Special warnings and precaution for use).

**Short acting opiates (CYP3A4 substrate)**

In an independent publication, steady-state administration of oral voriconazole increased the AUC∞ of a single dose of alfentanil by 6-fold. Reduction in the dose of alfentanil and other short acting opiates similar in structure to alfentanil and metabolised by CYP3A4 (e.g., sufentanil) should be considered when co-administered with voriconazole (see Section 4.4 Special warnings and precaution for use).

**Fentanyl (CYP3A4 substrate)**

In an independent published study, concomitant use of voriconazole (400 mg q12h on Day 1, then 200 mg q12h on Day 2) with a single intravenous dose of fentanyl (5 µg/kg) resulted in an increase in the mean AUC0-∞ of fentanyl by 1.4-fold (range 1.12-1.60-fold). When voriconazole is co-administered with fentanyl, extended and frequent monitoring of patients for respiratory depression and other fentanyl-associated adverse events is recommended, and the fentanyl dose should be reduced if warranted.

**Oxycodone (CYP3A4 substrate)**

In an independent publication, co-administration of multiple doses of oral voriconazole (400 mg q12h on Day 1, followed by five doses of 200 mg q12h on Days 2 to 4) with a single 10 mg oral dose of oxycodone on Day 3 resulted in an increase in the mean Cmax and AUC0-∞ of oxycodone by 1.7-fold (range 1.4- to 2.2-fold) and 3.6-fold (range 2.7- to 5.6-fold), respectively. The mean elimination half-life of oxycodone was also increased by 2.0-fold (range 1.4- to 2.5-fold). A reduction in oxycodone dosage may be needed during voriconazole treatment to avoid opioid related adverse effects. Extended and frequent monitoring for adverse effects associated with oxycodone and other long-acting opiates metabolised by CYP3A4 is recommended.

**Everolimus (CYP3A4 substrate, P-gP substrate)**

Although not studied, voriconazole is likely to significantly increase the plasma concentrations of everolimus. Co-administration of voriconazole and everolimus is not recommended because voriconazole is expected to significantly increase everolimus concentrations.
**Warfarin (CYP2C9 substrate)**

Co-administration of voriconazole (300 mg twice daily) with warfarin (30 mg single dose) increased maximum prothrombin time by 93%. Close monitoring of prothrombin time is recommended if warfarin and voriconazole are co-administered.

**Other oral anticoagulants (CYP2C9, CYP3A4 substrates)**

Although not studied, voriconazole may increase the plasma concentrations of coumarins and therefore may cause an increase in prothrombin time. If patients receiving coumarin preparations are treated simultaneously with voriconazole, the prothrombin time should be monitored at close intervals and the dosage of anticoagulants adjusted accordingly.

**Sulphonylureas (CYP2C9 substrates)**

Although not studied, voriconazole may increase the plasma levels of sulphonylureas, (e.g., tolbutamide, glipizide, and glyburide) and therefore cause hypoglycaemia. Careful monitoring of blood glucose is recommended during co-administration.

**Statins (CYP3A4 substrates)**

Although not studied clinically, voriconazole has been shown to inhibit lovastatin metabolism in vitro (human liver microsomes). Therefore, voriconazole is likely to increase plasma levels of statins that are metabolised by CYP3A4. It is recommended that dose adjustment of the statin be considered during co-administration. Increased statin levels have been associated with rhabdomyolysis.

**Benzodiazepines (CYP3A4 substrates)**

Although not studied clinically, voriconazole has been shown to inhibit midazolam metabolism in vitro (human liver microsomes). Therefore, voriconazole is likely to increase the plasma levels of benzodiazepines that are metabolised by CYP3A4 (e.g., midazolam, triazolam and alprazolam) and lead to a prolonged sedative effect. It is recommended that dose adjustment of the benzodiazepine be considered during co-administration.

**Vinca alkaloids (CYP3A4 substrates)**

Although not studied, voriconazole may increase the plasma levels of the vinca alkaloids (e.g., vincristine and vinblastine) and lead to neurotoxicity. It is therefore recommended that dose adjustment of the vinca alkaloid be considered.

**Non-steroidal anti-inflammatory drugs (NSAIDs)**

Voriconazole increased Cmax and AUC of ibuprofen (400 mg single dose) by 20% and 100%, respectively. Voriconazole increased Cmax and AUC of diclofenac (50 mg single dose) by 114% and 78%, respectively. Frequent monitoring for adverse events and toxicity relating to NSAIDs is recommended. Adjustment of dosage of NSAIDs may be needed.

No significant pharmacokinetic interactions were observed when voriconazole was co-administered with the following agents. No dosage adjustment for these agents is recommended.

**Prednisolone (CYP3A4 substrate)**

Voriconazole increased Cmax and AUC of prednisolone (60 mg single dose) by 11% and 34%, respectively. No dosage adjustment is recommended.
**Digoxin (P-glycoprotein mediated transport)**

Voriconazole had no significant effect on Cmax and AUC\(\tau\) of digoxin (0.25 mg once daily).

**Mycophenolic acid (UDP-glucuronyl transferase substrate)**

Voriconazole had no effect on the Cmax and AUC\(\tau\) of mycophenolic acid (1 g single dose).

**Two-way interactions**

**Phenytoin (CYP2C9 substrates and potent CYP450 inducer)**

Concomitant use of voriconazole and phenytoin should be avoided unless the benefit outweighs the risk. Phenytoin (300 mg once daily) decreased the Cmax and AUC\(\tau\) of voriconazole by 49% and 69%, respectively. Voriconazole (400 mg twice daily) increased Cmax and AUC\(\tau\) of phenytoin (300 mg once daily) by 67% and 81%, respectively.

Phenytoin may be co-administered with voriconazole if the maintenance dose of voriconazole is increased to 5 mg/kg intravenously twice daily or from 200 mg to 400 mg orally, twice daily (100 mg to 200 mg orally, twice daily in patients less than 40 kg). Careful monitoring of phenytoin plasma levels is recommended when phenytoin is co-administered with voriconazole.

**Omeprazole (CYP2C19 inhibitor; CYP2C19 and CYP3A4 substrate)**

Omeprazole (40 mg once daily) increased voriconazole Cmax and AUC\(\tau\) by 15% and 41%, respectively. No dosage adjustment of voriconazole is recommended. Voriconazole increased omeprazole Cmax and AUC\(\tau\) by 116% and 280%, respectively. When initiating voriconazole in patients already receiving omeprazole, it is recommended that the omeprazole dose be halved. The metabolism of other proton pump inhibitors which are CYP2C19 substrates may also be inhibited by voriconazole.

**Fluconazole (CYP2C9, CYP2C19 and CYP3A4 inhibitor)**

Fluconazole (200 mg once daily) increased the Cmax and AUC\(\tau\) of voriconazole by 57% and 79%, respectively. The Cmax and AUC\(\tau\) of fluconazole were not determined. The reduced dose and/or frequency of voriconazole and fluconazole that would eliminate this effect have not been established. Monitoring for voriconazole-associated adverse events is recommended if voriconazole is used sequentially after fluconazole.

**Oral contraceptives (CYP3A4 substrate)**

Co-administration of voriconazole and an oral contraceptive (noretihisterone 1 mg and ethinyloestradiol 0.035 mg once daily) in healthy female subjects resulted in increases in the Cmax and AUC\(\tau\) of ethinyloestradiol (36% and 61% respectively) and noretihisterone (15% and 53% respectively). Voriconazole Cmax and AUC\(\tau\) increased by 14% and 46% respectively. Oral contraceptives containing doses other than noretihisterone 1 mg and ethinyloestradiol 0.035 mg have not been studied. As the ratio between noretihisterone and ethinyloestradiol remained similar during interaction with voriconazole, their contraceptive activity would probably not be affected. Monitoring for adverse events related to oral contraceptives is recommended during co-administration.
**Indinavir (CYP3A4 inhibitor and substrate)**

Indinavir (800 mg three times daily) had no significant effect on voriconazole Cmax and AUCτ. Voriconazole did not have a significant effect on Cmax, Cmin and AUCτ of indinavir.

**Other HIV protease inhibitors (CYP3A4 substrates and inhibitors)**

*In vitro* studies suggest that voriconazole may inhibit the metabolism of HIV protease inhibitors (e.g., saquinavir, amprenavir and nelfinavir). *In vitro* studies also show that the metabolism of voriconazole may be inhibited by HIV protease inhibitors. Patients should be carefully monitored for drug toxicity during the co-administration of voriconazole and HIV protease inhibitors.

**Efavirenz (a non-nucleoside reverse transcriptase inhibitor [CYP450 inducer; CYP3A4 inhibitor and substrate])**

Use of standard doses of voriconazole with efavirenz doses of 400 mg once daily or higher is contraindicated (see Section 4.3 Contraindications).

In healthy subjects, steady state efavirenz (400 mg oral once daily) decreased the steady state Cmax and AUCτ of voriconazole by an average of 61% and 77%, respectively. In the same study, voriconazole at steady state (400 mg orally every 12 hours for 1 day, then 200 mg orally every 12 hours for 8 days) increased the steady state Cmax and AUCτ of efavirenz by an average of 38% and 44%, respectively, in the same subjects.

In a separate study in healthy subjects, voriconazole dose of 300 mg twice daily in combination with low dose efavirenz (300 mg once daily) did not lead to sufficient voriconazole exposure.

Following co-administration of voriconazole 400 mg twice daily with efavirenz 300 mg orally once daily in healthy subjects, the AUCτ of voriconazole was decreased by 7% and Cmax was increased by 23% compared to voriconazole 200 mg twice daily alone. The AUCτ of efavirenz was increased by 17% and Cmax was equivalent compared to efavirenz 600 mg once daily alone. These differences were not considered to be clinically significant.

Voriconazole may be co-administered with efavirenz if the voriconazole maintenance dose is increased to 400 mg twice daily and the efavirenz dose is reduced by 50%, i.e., to 300 mg once daily (see section 4.2 Dose and method of administration). When treatment with voriconazole is stopped, the initial dose of efavirenz should be restored.

The concomitant use of intravenous voriconazole and oral efavirenz has not been studied.

**Other non-nucleoside reverse transcriptase inhibitors (NNRTIs) (CYP3A4 substrates, inhibitors or CYP450 inducers)**

*In vitro* studies show that the metabolism of voriconazole may be inhibited by delavirdine. Although not studied, the metabolism of voriconazole may be induced by nevirapine. Voriconazole may also inhibit the metabolism of NNRTIs. Patients should be carefully monitored for drug toxicity during the co-administration of voriconazole and NNRTIs.
### Guidance on the clinical management of drug interactions

<table>
<thead>
<tr>
<th>Contraindications</th>
<th>Dose adjustment of voriconazole</th>
<th>Dose adjustment and/or monitoring of other drugs</th>
<th>No dose adjustment of voriconazole or other drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rifampicin</td>
<td>Phenytoin (1,3)</td>
<td>Cyclosporin (2,3)</td>
<td>Indinavir</td>
</tr>
<tr>
<td>Sirolimus</td>
<td></td>
<td>Tacrolimus (2,3)</td>
<td>Mycophenolate mofetil</td>
</tr>
<tr>
<td>Barbiturates (long acting)</td>
<td></td>
<td>Omeprazole (2)</td>
<td>Cimetidine</td>
</tr>
<tr>
<td>Carbamazepine</td>
<td></td>
<td>Warfarin (4)</td>
<td>Ranitidine</td>
</tr>
<tr>
<td>Cisapride</td>
<td></td>
<td>Phenytoin (3)</td>
<td>Macrolide antibiotics</td>
</tr>
<tr>
<td>Pimozide</td>
<td></td>
<td>Sulphonylureas (5)</td>
<td>Prednisolone</td>
</tr>
<tr>
<td>Quinidine</td>
<td></td>
<td>Statins (7)</td>
<td>Digoxin</td>
</tr>
<tr>
<td>Ergot alkaloids</td>
<td></td>
<td>Benzodiazepines (7)</td>
<td>No established dosing recommendation</td>
</tr>
<tr>
<td>St John’s Wort</td>
<td></td>
<td>Vinca Alkaloids (7)</td>
<td>Everolimus (8)</td>
</tr>
<tr>
<td>Rifabutin</td>
<td></td>
<td>Nevirapine (7)</td>
<td>Fluconazole (9)</td>
</tr>
<tr>
<td>Ritonavir (400 mg q12h)</td>
<td>Ritonavir (100 mg q12h)</td>
<td>HIV protease inhibitors (7)</td>
<td></td>
</tr>
<tr>
<td>Efavirenz (400 mg q24h)</td>
<td>Efavirenz (1)</td>
<td>(excluding indinavir &amp; ritonavir)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Methadone (7)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oral Contraceptive (7)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Short Acting Opiates including fentanyl (7)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>NSAIDs (7)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oxycodone (7)</td>
<td></td>
</tr>
</tbody>
</table>

1 See section 4.2 Dose and method of administration, Dosage adjustment.
2 Reduce dose (halve dose of cyclosporin and omeprazole, reduce dose to one third for tacrolimus)
3 Carefully monitor blood levels
4 Monitor prothrombin time
5 Monitor blood glucose
6 Monitor complete blood counts
7 Monitor for potential drug toxicity and consider dose reduction
8 Co-administration with voriconazole is not recommended
9 Monitor for voriconazole associated adverse events if voriconazole is used sequentially after fluconazole

### 4.6 Fertility, pregnancy and lactation

#### Fertility

Fertility of male and female rats was not affected at oral doses of up to 50 mg/kg/day, corresponding to exposures 4-6 times the expected human exposure (based on AUC) at the maintenance dose.
Pregnancy

Australian Pregnancy Category B3

Women of childbearing potential must always use effective contraception during treatment.

There are no adequate studies in pregnant women. Studies in rats have shown reproductive toxicity, including teratogenicity (cleft palates) at oral doses of $\geq 10 \text{ mg/kg/day}$ and disturbance of parturition (dystocia) at oral doses of $\geq 3 \text{ mg/kg/day}$, with exposures similar to or below those expected in humans at maintenance dosing. Voriconazole was not teratogenic in rabbits at oral doses of up to 100 mg/kg/day, but produced an increase in post-implantation loss and a decrease in fetal body weight, with exposures approximately 4 times the expected human exposure. Voriconazole must not be used during pregnancy except in patients with severe or potentially life-threatening fungal infections in whom voriconazole may be used if the benefit to the mother clearly outweighs the potential risk to the foetus.

Lactation

It is not known whether voriconazole is excreted in the milk of laboratory animals or in human breast milk. Breast-feeding must be stopped on initiation of treatment with voriconazole.

4.7 Effects on ability to drive and use machinery

Voriconazole may cause changes to vision, including blurring, altered/enhanced visual perception and/or photophobia. Patients must avoid potentially hazardous tasks, such as driving or operating machinery whilst experiencing these symptoms. Patients should be advised not to drive at night while taking voriconazole.

4.8 Undesirable effects

Clinical trial data

The safety of voriconazole in adults is based on an integrated safety database of more than 2000 subjects (1603 adult patients in therapeutic studies). This represents a heterogeneous population, containing patients with haematological malignancy, HIV infected patients with oesophageal candidiasis and refractory fungal infections, non-neutropenic patients with candidaemia or aspergillosis and healthy volunteers.

The table below includes all causality adverse reactions in 1603 adults from pooled therapeutic studies. The most commonly reported adverse events were visual impairment, liver function test abnormal, pyrexia, rash, vomiting, nausea, diarrhoea, headache, peripheral oedema and abdominal pain. The severity of the adverse events was generally mild to moderate. No clinically significant differences were seen when the safety data were analysed by age, race, or gender.

<table>
<thead>
<tr>
<th>MedDRA System Organ Class Frequency†</th>
<th>Adverse drug reactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infections and infestations</td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td>Sinusitis</td>
</tr>
<tr>
<td>Uncommon</td>
<td>Pseudomembranous colitis</td>
</tr>
<tr>
<td>MedDRA System Organ Class Frequency†</td>
<td>Adverse drug reactions</td>
</tr>
<tr>
<td>-------------------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td><strong>Blood and lymphatic system disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td>Agranulocytosis, pancytopenia, thrombocytopenia, leukopenia, anaemia</td>
</tr>
<tr>
<td>Uncommon</td>
<td>Bone marrow failure, lymphadenopathy, eosinophilia</td>
</tr>
<tr>
<td>Rare</td>
<td>Disseminated intravascular coagulation</td>
</tr>
<tr>
<td><strong>Immune system disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Uncommon</td>
<td>Hypersensitivity</td>
</tr>
<tr>
<td>Rare</td>
<td>Anaphylactoid reaction</td>
</tr>
<tr>
<td><strong>Endocrine disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Uncommon</td>
<td>Adrenal insufficiency, hypothyroidism</td>
</tr>
<tr>
<td>Rare</td>
<td>Hyperthyroidism</td>
</tr>
<tr>
<td><strong>Metabolism and nutrition disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Very common</td>
<td>Oedema peripheral</td>
</tr>
<tr>
<td>Common</td>
<td>Hypoglycaemia, hypokalaemia, hyponatraemia</td>
</tr>
<tr>
<td><strong>Psychiatric disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td>Depression, hallucination, anxiety, insomnia, agitation, confusional state</td>
</tr>
<tr>
<td><strong>Nervous system disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Very common</td>
<td>Headache</td>
</tr>
<tr>
<td>Common</td>
<td>Syncope, tremor, hypertonia, paraesthesia, somnolence, dizziness</td>
</tr>
<tr>
<td>Uncommon</td>
<td>Brain oedema, encephalopathy, extrapyramidal disorder, neuropathy peripheral, ataxia, hypoaesthesia, dysgeusia</td>
</tr>
<tr>
<td>Rare</td>
<td>Hepatic encephalopathy, Guillain-Barré syndrome, seizure, nystagmus</td>
</tr>
<tr>
<td><strong>Eye disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Very common</td>
<td>Visual impairment</td>
</tr>
<tr>
<td>Common</td>
<td>Retinal haemorrhage</td>
</tr>
<tr>
<td>Uncommon</td>
<td>Papilloedema, oculogyric crisis, diplopia, scleritis, blepharitis</td>
</tr>
<tr>
<td>Rare</td>
<td>Optic atrophy, optic nerve disorder, corneal opacity</td>
</tr>
<tr>
<td><strong>Ear and labyrinth disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Uncommon</td>
<td>Hypoacusis, vertigo, tinnitus</td>
</tr>
<tr>
<td><strong>Cardiac disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td>Arrhythmia supraventricular, tachycardia, bradycardia</td>
</tr>
<tr>
<td>Uncommon</td>
<td>Ventricular fibrillation, ventricular extrasystoles, ventricular tachycardia, electrocardiogram QT prolonged, supraventricular tachycardia</td>
</tr>
<tr>
<td>Rare</td>
<td>Torsades de pointes, atrioventricular block complete, bundle branch block, nodal rhythm</td>
</tr>
<tr>
<td><strong>Vascular disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td>Hypotension, phlebitis</td>
</tr>
<tr>
<td>Uncommon</td>
<td>Thrombophlebitis, lymphangitis</td>
</tr>
<tr>
<td>MedDRA System Organ Class Frequency†</td>
<td>Adverse drug reactions</td>
</tr>
<tr>
<td>-------------------------------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td><strong>Respiratory, thoracic and mediastinal disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td>Acute respiratory distress syndrome, pulmonary oedema</td>
</tr>
<tr>
<td><strong>Gastrointestinal disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Very common</td>
<td>Diarrhoea, vomiting, nausea</td>
</tr>
<tr>
<td>Common</td>
<td>Cheilitis, dyspepsia, abdominal pain, constipation, gingivitis</td>
</tr>
<tr>
<td>Uncommon</td>
<td>Peritonitis, pancreatitis, swollen tongue, duodenitis, gastroenteritis, glossitis</td>
</tr>
<tr>
<td><strong>Hepatobiliary disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Very common</td>
<td>Liver function test abnormal</td>
</tr>
<tr>
<td>Common</td>
<td>Jaundice, jaundice cholestatic</td>
</tr>
<tr>
<td>Uncommon</td>
<td>Hepatic failure, hepatitis, hepatomegaly, cholecystitis, cholelithiasis</td>
</tr>
<tr>
<td><strong>Skin and subcutaneous tissue disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Very common</td>
<td>Rash</td>
</tr>
<tr>
<td>Common</td>
<td>Dermatitis exfoliative, alopecia, purpura, rash maculopapular, pruritus</td>
</tr>
<tr>
<td>Uncommon</td>
<td>Stevens-Johnson syndrome(^a), photosensitivity reaction, urticaria</td>
</tr>
<tr>
<td>Rare</td>
<td>Toxic epidermal necrolysis(^g), drug reaction with eosinophilia and systemic symptoms (DRESS)(^g), angioedema, pseudoporphyria, erythema multiforme, psoriasis, drug eruption, eczema</td>
</tr>
<tr>
<td><strong>Musculoskeletal, connective tissue and bone disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td>Back pain</td>
</tr>
<tr>
<td>Uncommon</td>
<td>Arthritis</td>
</tr>
<tr>
<td><strong>Renal and urinary disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td>Renal failure acute, haematuria</td>
</tr>
<tr>
<td>Uncommon</td>
<td>Renal tubular necrosis, proteinuria, nephritis</td>
</tr>
<tr>
<td><strong>General disorders and administration site conditions</strong></td>
<td></td>
</tr>
<tr>
<td>Very common</td>
<td>Pyrexia</td>
</tr>
<tr>
<td>Common</td>
<td>Chest pain, face oedema(^j), asthenia, chills</td>
</tr>
<tr>
<td>Uncommon</td>
<td>Infusion site reaction, influenza-like illness</td>
</tr>
<tr>
<td><strong>Investigations</strong></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td>Blood creatinine increased</td>
</tr>
<tr>
<td>Uncommon</td>
<td>Blood urea increased, blood cholesterol increased</td>
</tr>
</tbody>
</table>

†Frequencies are categorised as follows: very common ≥10%; common from ≥1% to <10%; uncommon from ≥0.1% to <1%; rare from 0.01% to <0.1%)

\(^a\) Includes febrile neutropenia and neutropenia

\(^b\) Includes immune thrombocytopenic purpura

\(^c\) Includes nuchal rigidity and tetany

\(^d\) Includes hypoxic-ischaemic encephalopathy and metabolic encephalopathy

\(^e\) Includes akathisia and parkinsonism

\(^f\) Includes apraxia, ataxia, dystonia, dyskinesia, extrapyramidal disorder, parkinsonism, tardive dyskinesia

\(^g\) See Section 4.4 Special warnings and precautions for use

\(^h\) Includes optic neuritis and retinopathy

\(^i\) Includes optic neuritis and retinopathy

\(^j\) Includes optic neuritis and retinopathy

\(^k\) Includes optic neuritis and retinopathy

\(^l\) Includes optic neuritis and retinopathy

\(^m\) Includes optic neuritis and retinopathy

\(^n\) Includes optic neuritis and retinopathy

\(^o\) Includes optic neuritis and retinopathy

\(^p\) Includes optic neuritis and retinopathy

\(^q\) Includes optic neuritis and retinopathy

\(^r\) Includes optic neuritis and retinopathy

\(^s\) Includes optic neuritis and retinopathy

\(^t\) Includes optic neuritis and retinopathy

\(^u\) Includes optic neuritis and retinopathy

\(^v\) Includes optic neuritis and retinopathy

\(^w\) Includes optic neuritis and retinopathy

\(^x\) Includes optic neuritis and retinopathy

\(^y\) Includes optic neuritis and retinopathy

\(^z\) Includes optic neuritis and retinopathy
Adverse events reported in comparative therapeutic studies 305 and 307/602 at a rate of ≥ 1% possibly related to therapy or causality unknown

<table>
<thead>
<tr>
<th>Blood and lymphatic system disorders</th>
<th>Protocol 305 voriconazole vs fluconazole (oral therapy)</th>
<th>Protocol 307/602 voriconazole vs conventional amphotericin B (IV/oral therapy)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N (%)</td>
<td>N (%)</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>-</td>
<td>2 (1.0)</td>
</tr>
<tr>
<td>Anaemia</td>
<td>-</td>
<td>5 (2.7)</td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>N (%)</td>
<td>N (%)</td>
</tr>
<tr>
<td>Hypokalaemia</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hypomagnesaemia</td>
<td>-</td>
<td>2 (1.0)</td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>N (%)</td>
<td>N (%)</td>
</tr>
<tr>
<td>Hallucinations</td>
<td>-</td>
<td>10 (5.1)</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>N (%)</td>
<td>N (%)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>-</td>
<td>5 (2.6)</td>
</tr>
<tr>
<td>Eye disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abnormal vision</td>
<td>31 (15.5)</td>
<td>55 (28.1)</td>
</tr>
<tr>
<td>Photophobia</td>
<td>5 (2.5)</td>
<td>7 (3.6)</td>
</tr>
<tr>
<td>Chromatopsia</td>
<td>2 (1.0)</td>
<td>2 (1.0)</td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tachycardia</td>
<td>-</td>
<td>5 (2.6)</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>-</td>
<td>2 (1.1)</td>
</tr>
<tr>
<td>Hypotension</td>
<td>-</td>
<td>3 (1.6)</td>
</tr>
<tr>
<td>Vasodilatation</td>
<td>-</td>
<td>2 (1.1)</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>-</td>
<td>5 (2.6)</td>
</tr>
<tr>
<td>Nausea</td>
<td>2 (1.0)</td>
<td>14 (7.1)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>2 (1.0)</td>
<td>11 (5.6)</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>-</td>
<td>3 (1.5)</td>
</tr>
<tr>
<td>Dry mouth</td>
<td>-</td>
<td>3 (1.5)</td>
</tr>
<tr>
<td>Hepatobiliary disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cholestatic jaundice</td>
<td>3 (1.5)</td>
<td>4 (2.0)</td>
</tr>
<tr>
<td>Bilirubinaemia</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>-</td>
<td>7 (3.6)</td>
</tr>
<tr>
<td>Rash</td>
<td>3 (1.5)</td>
<td>13 (6.6)</td>
</tr>
<tr>
<td>Pruritus</td>
<td>-</td>
<td>2 (1.0)</td>
</tr>
</tbody>
</table>

1 Includes drug-induced liver injury, hepatitis toxic, hepatocellular injury and hepatotoxicity
2 Includes periorbital oedema, lip oedema and oedema mouth
Protocol 305
voriconazole vs fluconazole (oral therapy)

<table>
<thead>
<tr>
<th></th>
<th>vori N = 200</th>
<th>fluc N = 191</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maculopapular rash</td>
<td>3 (1.5)</td>
<td>-</td>
</tr>
<tr>
<td>Renal and urinary disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kidney function abnormal</td>
<td>-</td>
<td>4 (2.0)</td>
</tr>
<tr>
<td>Acute kidney failure</td>
<td>-</td>
<td>11 (5.9)</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peripheral oedema</td>
<td>-</td>
<td>7 (3.6)</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>-</td>
<td>7 (3.6)</td>
</tr>
<tr>
<td>Chills</td>
<td>-</td>
<td>4 (2.0)</td>
</tr>
<tr>
<td>Chest pain</td>
<td>-</td>
<td>2 (1.0)</td>
</tr>
<tr>
<td>Investigations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver function tests abnormal</td>
<td>6 (3.0)</td>
<td>2 (1.0)</td>
</tr>
<tr>
<td>Alkaline phosphatase increased</td>
<td>10 (5.0)</td>
<td>3 (1.6)</td>
</tr>
<tr>
<td>Hepatic enzymes increased</td>
<td>3 (1.5)</td>
<td>7 (3.6)</td>
</tr>
<tr>
<td>AST (SGOT) increased</td>
<td>8 (4.0)</td>
<td>2 (1.0)</td>
</tr>
<tr>
<td>Creatinine increased</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>ALT (SGPT) increased</td>
<td>6 (3.0)</td>
<td>2 (1.0)</td>
</tr>
</tbody>
</table>

Protocol 307/602
voriconazole vs conventional amphotericin B (IV/oral therapy)

<table>
<thead>
<tr>
<th></th>
<th>vori N = 196</th>
<th>ampho B* N = 185</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maculopapular rash</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Renal and urinary disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kidney function abnormal</td>
<td>40 (21.6)</td>
<td>-</td>
</tr>
<tr>
<td>Acute kidney failure</td>
<td>11 (5.9)</td>
<td>-</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peripheral oedema</td>
<td>9 (4.9)</td>
<td>-</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>25 (13.5)</td>
<td>-</td>
</tr>
<tr>
<td>Chills</td>
<td>36 (19.5)</td>
<td>-</td>
</tr>
<tr>
<td>Chest pain</td>
<td>2 (1.1)</td>
<td>-</td>
</tr>
<tr>
<td>Investigations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver function tests abnormal</td>
<td>9 (4.6)</td>
<td>4 (2.2)</td>
</tr>
<tr>
<td>Alkaline phosphatase increased</td>
<td>6 (3.1)</td>
<td>4 (2.2)</td>
</tr>
<tr>
<td>Hepatic enzymes increased</td>
<td>7 (3.6)</td>
<td>5 (2.7)</td>
</tr>
<tr>
<td>AST (SGOT) increased</td>
<td>3 (1.5)</td>
<td>-</td>
</tr>
<tr>
<td>Creatinine increased</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>ALT (SGPT) increased</td>
<td>59 (31.9)</td>
<td>-</td>
</tr>
</tbody>
</table>

*Amphotericin B followed by other licensed antifungal therapy

Description of selected adverse reactions

Visual impairment

In clinical trials, visual impairments (including blurred vision, photophobia, chloropsia, chromatopsia, colour blindness, cyanopsia, eye disorder, halo vision, night blindness, oscillopsia, photopsia, scintillating scotoma, visual acuity reduced, visual brightness, visual field defect, vitreous floaters and xanthopsia) with voriconazole were very common. These visual impairments were transient and fully reversible, with the majority spontaneously resolving within 60 minutes. There was evidence of attenuation with repeated doses of voriconazole. The visual impairments were generally mild, rarely resulted in discontinuation and were not associated with long-term sequelae. Visual impairments may be associated with higher plasma concentrations and/or doses.

There have been post-marketing reports of prolonged visual adverse events (see Section 4.4 Special warnings and precautions for use).

The mechanism of action is unknown, although the site of action is most likely to be within the retina.

In a study in healthy volunteers investigating the impact of voriconazole on retinal function, voriconazole caused a decrease in the electroretinogram (ERG) waveform amplitude. The ERG measures electrical currents in the retina. The ERG changes did not progress over 29 days of treatment and were fully reversible on withdrawal of voriconazole.
The long-term effect of voriconazole (median 169 days; range 5-353 days) on visual function was evaluated in subjects with paracoccidioidomycoses. Voriconazole had no clinically relevant effect on visual function as assessed by testing of visual acuity, visual fields, colour vision and contrast sensitivity. There were no signs of retinal toxicity. 17/35 voriconazole subjects experienced visual adverse events. These events did not lead to discontinuation, were generally mild, occurred in the first week of therapy and resolved during continued voriconazole therapy.

**Dermatological reactions**

Dermatological reactions were very common in patients treated with voriconazole. In clinical trials, rashes were reported by 19% (278/1493) of voriconazole treated patients, but these patients had serious underlying diseases and were receiving multiple concomitant medications. The majority of rashes were of mild to moderate severity. Patients have developed serious cutaneous reactions, including Stevens-Johnson syndrome (uncommon), toxic epidermal necrolysis (rare) and erythema multiforme (rare) during treatment with voriconazole.

If patients develop a rash they should be monitored closely and voriconazole discontinued if lesions progress. Photosensitivity reactions have been reported, especially during long-term therapy (see Section 4.4 Special warnings and precautions for use).

Dermatological adverse reactions potentially related to phototoxicity (pseudoporphyria, cheilitis, and cutaneous lupus erythematosus) are also reported with voriconazole. Sun avoidance and photoprotection are recommended for all patients. If phototoxicity occurs, voriconazole discontinuation and dermatological evaluation should be considered (see Section 4.4 Special warnings and precautions for use).

There have been post-marketing reports of cutaneous lupus erythematosus and squamous cell carcinoma (SCC) (see Section 4.4 Special warnings and precautions for use).

**Liver function tests**

The overall incidence of clinically significant transaminase abnormalities in the voriconazole clinical program was 13.4% (200/1493) of subjects treated with voriconazole. Liver function test abnormalities may be associated with higher plasma concentrations and/or doses. The majority of abnormal liver function tests either resolved during treatment without dose adjustment or following dose adjustment, including discontinuation of therapy.

Voriconazole has been associated with cases of serious hepatic toxicity, in patients with other serious underlying conditions. This includes cases of jaundice, hepatitis and hepatic failure leading to death (see Section 4.4 Special warnings and precautions for use).

**Infusion-related reactions**

During infusion of the intravenous formulation of voriconazole in healthy subjects, anaphylactoid-type reactions, including flushing, fever, sweating, tachycardia, chest tightness, dyspnoea, faintness, nausea, pruritus and rash have occurred. Symptoms appeared immediately upon initiating the infusion (see Section 4.4 Special warnings and precautions for use).

**Paediatric use**

The safety of voriconazole was investigated in 245 paediatric patients aged 2 to <12 years who were treated with voriconazole in pharmacokinetic studies (87 paediatric patients) and in
compassionate use programs (158 paediatric patients). The adverse event profile of these 245 paediatrics was similar to adults. A higher frequency of liver enzyme elevations reported as adverse events was observed in paediatric patients as compared to adults.

Post-marketing data suggest there might be a higher occurrence of skin reactions in the paediatric population compared to adults.

There have been post-marketing reports of pancreatitis in paediatric patients.

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions [https://nzphvc.otago.ac.nz/reporting/](https://nzphvc.otago.ac.nz/reporting/).

**4.9 Overdose**

Clinical data on overdose with this agent is scant.

In clinical trials there were three cases of accidental overdose. All occurred in paediatric patients, who received up to five times the recommended intravenous dose of voriconazole. A single adverse event of photophobia of 10 minutes duration was reported.

There is no known antidote to voriconazole. It is recommended that treatment of overdose is symptomatic and supportive.

Monitor potassium, full blood count and liver function following an overdose.

Consider administration of activated charcoal in the event of a potentially toxic ingestion. Activated charcoal is most effective when administered within one hour of ingestion. In patients who are not fully conscious or have impaired gag reflex, consideration should be given to administering activated charcoal via nasogastric tube once the airway is protected.

Voriconazole is haemodialysed with a clearance of 121 mL/min. The intravenous vehicle, SBECID, is haemodialysed with a clearance of 55 mL/min. In an overdose, haemodialysis may assist in the removal of voriconazole and SBECID from the body.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

**5. PHARMACOLOGICAL PROPERTIES**

**5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Antimycotics for systemic use, triazole derivatives, ATC code: J02 AC03.
Mechanism of action

Voriconazole is a triazole antifungal agent. Voriconazole’s primary mode of action is the inhibition of fungal cytochrome P-450-mediated 14α-lanosterol demethylation, an essential step in ergosterol biosynthesis. Voriconazole is more selective than some other azole drugs for fungal as opposed to various mammalian cytochrome P-450 enzyme systems. The subsequent loss of normal sterols correlates with the accumulation of 14α-methyl sterols in fungi and may be responsible for its fungistatic/fungicidal activity.

In vitro, voriconazole displays broad-spectrum antifungal activity with high antifungal potency against Candida species (including fluconazole resistant C. krusei and resistant strains of C. glabrata and C. albicans) and fungicidal activity against all Aspergillus species tested. In addition, voriconazole shows in vitro activity against emerging fungal pathogens, such as Scedosporium or Fusarium, some isolates of which have limited susceptibility to existing antifungal agents. In addition, voriconazole exhibits in vitro fungicidal activity against some strains within these species.

In animal studies there is a correlation between minimum inhibitory concentration values and efficacy against experimental mycoses. Furthermore, there appears to be a correlation between minimum inhibitory concentration values and clinical outcome for Candida species.

Voriconazole drug substance is a white to off white powder. Its aqueous solubility is very low at 0.7 mg/mL at 25°C.

Voriconazole is designated chemically as (2R, 3S)-2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol with an empirical formula of C$_{16}$H$_{14}$F$_{3}$N$_{5}$O and a molecular weight of 349.3. The structural formula is

![Chemical structure of voriconazole](image)

CAS number is 137234-62-9.

Microbiology

Clinical efficacy (with partial or complete response, see Section 5.2 Clinical safety and efficacy, Clinical experience) has been demonstrated for Aspergillus spp. including A. flavus, A. fumigatus, A. terreus, A. niger, A. nidulans, Candida spp., including C. albicans, C. dubliniensis, C. glabrata, C. inconspicua, C. krusei, C. parapsilosis, C. tropicalis and C. guilliermondii, Scedosporium spp., including S. apiospermum, S. prolificans and Fusarium spp.

Other treated fungal infections (with often partial or complete response) included isolated cases of Alternaria spp., Blastomyces dermatitidis, Blastoschizomyces capitatus, Cladosporium spp.,
Coccidioides immitis, Conidiobolus coronatus, Cryptococcus neoformans, Exserohilum rostratum, Exophiala spinifera, Fonsecaea pedrosoi, Madurella mycetomatis, Paecilomyces lilacinus, Penicillium spp including P. marneffei, Phialophora richardiae, Scopulariopsis brevicaulis and Trichosporon spp including T. beigelii infections.

*In vitro* activity against clinical isolates has been observed for *Acremonium* spp., *Alternaria* spp., *Bipolaris* spp., *Cladophialophora* spp, *Histoplasma capsulatum*, with most strains being inhibited by concentrations of voriconazole in the range 0.05 to 2 µg/mL.

*In vitro* activity against the following pathogens has been shown, but the clinical significance is unknown: *Curvularia* spp. and *Sporothrix* spp.

Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained to isolate and identify causative organisms prior to therapy. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly.

Clinical isolates with decreased susceptibility to voriconazole have been identified. However, elevated Minimum Inhibitory Concentrations (MIC) did not always correlate with clinical failure and clinical success has been observed in patients infected with organisms resistant to other azoles. Correlation of *in vitro* activity with clinical outcome is difficult owing to the complexity of the patients studied in clinical trials; breakpoints for voriconazole remain to be established.

**Clinical efficacy and safety**

*Duration of treatment*

In clinical trials, 561 patients received voriconazole therapy for greater than 12 weeks, with 136 subjects receiving voriconazole for over 6 months.

**Clinical experience**

Successful outcome in this section is defined as complete or partial response.

**Invasive aspergillosis**

The efficacy and survival benefit of voriconazole compared to conventional amphotericin B in the primary treatment of acute invasive aspergillosis was demonstrated in an open, randomised, multicentre study. The total duration of treatment was 12 weeks. Patients could be switched to Other Licensed Antifungal Therapy (OLAT) during the 12 week study period, either due to lack of efficacy of the initial randomised treatment (IRT) or for safety/tolerability reasons. Efficacy was assessed at 12 weeks (primary endpoint) and at the end of IRT by a Data Review Committee. Voriconazole was administered intravenously with a loading dose of 6 mg/kg every 12 hours for the first 24 hours followed by a maintenance dose of 4 mg/kg every 12 hours for a minimum of seven days, after which the oral formulation at a dose of 200 mg twice daily could be used. Patients in the comparator group received conventional amphotericin B as a slow infusion at a daily dose of 1.0-1.5 mg/kg/day.

In this study, 277 immunocompromised patients with invasive aspergillosis (modified intent to treat population) were evaluated. At week 12, a satisfactory global response (complete or partial resolution of all attributable symptoms, signs, radiographic/bronchoscopic abnormalities present at baseline) was seen in 53% of patients in the voriconazole group.
compared to 31% of patients in the comparator group. At the end of IRT, a satisfactory global response was seen in 53.5% of voriconazole treated patients compared to 21.8% of conventional amphotericin B treated patients. Subjects in the voriconazole group were treated longer than subjects in the amphotericin B group before switching to OLAT (median duration of IRT was 73 vs 12 days respectively). OLAT included liposomal amphotericin B formulations, itraconazole and flucytosine. Survival in the voriconazole group (71%) was greater than in the comparator group (58%) at week 12.

Efficacy of voriconazole in the primary treatment of acute invasive aspergillosis

<table>
<thead>
<tr>
<th>Satisfactory global response</th>
<th>Survival at week 12(^b)</th>
<th>Discontinuations due to AEs(^c)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study 307/602(^a)</td>
<td>Study 307/602</td>
<td>Study 307/602</td>
</tr>
<tr>
<td>Voriconazole</td>
<td>76/144 (53%)(^e)</td>
<td>102/144 (71%)</td>
</tr>
<tr>
<td>Comparator</td>
<td>42/133 (31%)(^d,e)</td>
<td>77/133 (58%)</td>
</tr>
<tr>
<td>p &lt;0.0001</td>
<td>p=0.02</td>
<td>--</td>
</tr>
</tbody>
</table>

\(a\) MITT (modified intent to treat) population assessed by independent Data Review Committee
\(b\) MITT population proportion of subjects alive
\(c\) Safety population discontinuations from initial randomised treatment due to adverse events/laboratory abnormalities (all causality)
\(d\) Amphotericin B
\(e\) Response rate stratified by protocol

The results of this comparative trial confirmed the results of an earlier trial in the primary treatment of patients with acute invasive aspergillosis (Study 304). In this study, an overall success rate of 54% was seen in patients treated with voriconazole.

Voriconazole successfully treated cerebral, sinus, pulmonary and disseminated aspergillosis in patients with bone marrow and solid organ transplants, haematological malignancies, cancer and AIDS.

**Serious candida infections**

**Systemic candida infections**

The efficacy of voriconazole compared to the regimen of (conventional) amphotericin B followed by fluconazole in the primary treatment of candidaemia was demonstrated in an open comparative study (number 150-608). Three hundred and seventy (370) non-neutropenic patients with documented candidaemia (positive blood culture and clinical signs of infection) were included in the study, of which 248 were treated with voriconazole. The patient population was seriously ill, with approximately 50% of subjects in the intensive care unit and 40% mechanically ventilated at baseline. The median treatment duration was 15 days in both treatment arms. A successful response (resolution/improvement in all clinical signs and symptoms of infection, blood cultures negative for \textit{Candida}, infected deep tissue sites negative for \textit{Candida}) was seen in 41% of patients in both treatment arms 12 weeks after the End of Therapy (EOT). In this analysis, patients who did not have an assessment 12 weeks after EOT were set to failure. According to a secondary analysis, which compared response rates at the latest time point most relevant to the evaluation of the patient (EOT, or 2, 6, or 12 weeks after EOT, which is more appropriate for this type of study), voriconazole and the regimen of amphotericin B followed by fluconazole had response rates of 65% and 71%, respectively. Forty-seven percent of isolated pathogens in the voriconazole treatment group were from non-
*albicans* species, including *C. glabrata* and *C. krusei*, although *C. albicans* was the most commonly isolated species in the small subgroup of patients (n = 14) with confirmed deep tissue infections. When considering response at 12 weeks after EOT by pathogen, the success rates were comparable between voriconazole (43%) and amphotericin B followed by fluconazole (46%) for baseline *Candida albicans* infections. Success rates were more favourable with voriconazole (38.6%) than with amphotericin followed by fluconazole (32.3%) for baseline non-*albicans* infections.

**Refractory candida infections**

Study 309/604 (the combined results of 2 open-label, non-comparative trials) assessed voriconazole in the treatment of fungal infections in patients refractory to, or intolerant of, other antifungal medications. Of the 301 patients assessed for efficacy, 87 patients had serious candidiasis: 38 had oesophageal candidiasis and 47 had invasive candidiasis, of which 26 patients had deep tissue *Candida* infections. The median duration of IV therapy was 11 days (range 1-138 days) and of oral therapy was 81 days (range 1-326 days). Overall 25/47 (53.2%) of invasive candidiasis subjects had a successful response, with 16/47 (34.0%) having a complete response and 9/47 (19.1%) having a partial response; 6/47 (12.8%) were assessed as stable. Of the subjects with deep tissue *Candida* infection, 14/26 (53.8%) had a successful response, with 8/26 (30.8%) having a complete response, 6/26 (23.1%) having a partial response and 5/26 (19.2%) assessed as stable.

**Oesophageal candidiasis**

Study 150-305 was a randomised, double-blind, comparative study versus oral fluconazole in immunocompromised patients with endoscopically-proven oesophageal candidiasis. 200 patients were randomised to receive voriconazole (200 mg twice daily) and 191 to receive fluconazole (400 mg once daily on day 1 followed by 200 mg once daily from day 2 onwards). Over half of the patients in each group had advanced AIDS with CD4 cell counts <50 cells/µL. Outcome was assessed by repeat endoscopy at day 43 or the end of therapy. Voriconazole and fluconazole showed equivalent efficacy against oesophageal candidiasis in the per protocol and intention to treat analysis.

### Efficacy of voriconazole in the treatment of oesophageal candidiasis

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Success/total (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PP</td>
</tr>
<tr>
<td>Voriconazole</td>
<td>113/115 (98%)</td>
</tr>
<tr>
<td>Fluconazole</td>
<td>134/141 (95%)</td>
</tr>
</tbody>
</table>

**Other serious fungal pathogens**

The efficacy, safety and tolerability of voriconazole in the treatment of systemic and invasive fungal infections in patients failing, or intolerant to other therapy, or for invasive fungal infections due to pathogens for which there is no licensed therapy was assessed in two, open, non-comparative studies (Studies 309/604). A total of 301 patients were evaluated for efficacy, of whom 72 cases had invasive infections due to fungal pathogens other than *Aspergillus* spp. or *Candida* spp.

Patients received an initial intravenous loading dose of 6 mg/kg q12h or an oral loading dose of 400 mg for the first 24 hours, followed by maintenance dosing with 4 mg/kg q12h or 200 mg
twice daily, respectively, for up to 12 weeks. The primary endpoint was satisfactory global response at End of Therapy, defined as ‘complete’ or ‘partial’ global response.

Overall 39/72 (54.2%) subjects with other (non-Aspergillus, non-Candida) serious fungal infections had a satisfactory global outcome at end of voriconazole therapy.

In pooled analyses of patients enrolled across the development program, including those from the combined 309/604 studies, voriconazole was shown to be effective against the following additional fungal pathogens:

*Scedosporium* spp.- Successful response to voriconazole therapy was seen in 16 of 28 patients with *S. apiospermum* and in 2 of 7 patients with *S. prolificans* infection. In addition, a successful response was seen in 1 of 3 patients with mixed organism infections.

*Fusarium* spp.- Seven of 17 patients were successfully treated with voriconazole. Of these seven patients, 3 had eye, 1 had sinus, and 3 had disseminated infection. Four additional patients with fusariosis had an infection caused by several organisms; two of them had a successful outcome.

The majority of patients receiving voriconazole treatment for rare fungal infections were intolerant of, or refractory to, prior antifungal therapy.

Other successfully treated fungal infections included isolated cases of: *Alternaria* spp., *Blastomycosis dermatitidis*, *Blastoschizomyces capitatus*, *Cladosporium* spp., *Coccidiodes immitis*, *Conidiobolus coronatus*, *Cryptococcus neoformans*, *Exserohilum rostratum*, *Exophiala spinifera*, *Fonsecaea pedrosoi*, *Madurella mycetomatis*, *Paecilomyces lilacinus*, *Penicillium* spp including *P. marneffei*, *Phialophora richardsiae*, *Scopulariopsis brevicaulis*, and *Trichosporon* spp. including *T. beigelii* infections.

**Clinical studies examining QT interval**

A placebo-controlled, randomised, single-dose, crossover study to evaluate the effect on the QT interval of healthy volunteers was conducted with three oral doses of voriconazole and ketoconazole. The placebo-adjusted mean maximum increases in QTc from baseline after 800, 1200 and 1600 mg of voriconazole were 5.1, 4.8, and 8.2 msec respectively and 7.0 msec for ketoconazole 800 mg. No subject in any group had an increase in QTc of ≥60 msec from baseline. No subject experienced an interval exceeding the potentially clinically relevant threshold of 500 msec. Subjects who were CYP2C19 genotype poor metabolisers were excluded from this study however the dose of 1600 mg voriconazole achieved plasma concentrations of approximately 5,400 to 16,900 ng/mL which covered the exposure seen in 95% of patients in Phase 2/3 trials where poor metabolisers were not excluded.

**Paediatric population**

Fifty-three pediatric patients aged 2 to <18 years were treated with voriconazole in two prospective, open-label, non-comparative, multi-center clinical trials. One study enrolled 31 patients with possible, proven or probable invasive aspergillosis (IA), of whom 14 patients had proven or probable IA and were included in the MITT efficacy analyses. The second study enrolled 22 patients with invasive candidiasis including candidaemia (ICC), or esophageal candidiasis (EC) requiring either primary or salvage therapy, of whom 17 patients were included in the MITT efficacy analyses. Of the total of 31 patients included in the MITT analyses, 14 patients were 2 to <12 years old (5 patients with IA, and 9 patients with ICC or
EC) and 17 patients were 12 to <18 years old (9 patients with IA, and 8 patients with ICC or EC). The overall rates of global response were 64.3% (9/14) at 6 weeks for patients with IA, 85.7% (6/7) at EOT for patients with ICC, and 70% (7/10) at EOT for patients with EC. In subjects with IA, the success rate was 40% (2/5) for patients 2 to <12 years and 77.8% (7/9) for patients 12 to <18 years of age.

5.2 Pharmacokinetic properties

General pharmacokinetic characteristics

The pharmacokinetics of voriconazole have been characterised in healthy subjects, special populations and patients. During oral administration of 200 mg or 300 mg twice daily for 14 days in patients at risk of aspergillosis (mainly patients with malignant neoplasms of lymphatic or haematopoietic tissue), the observed pharmacokinetic characteristics of rapid and consistent absorption, accumulation and non-linear pharmacokinetics were in agreement with those observed in healthy subjects.

The pharmacokinetics of voriconazole are non-linear due to saturation of its metabolism. Greater than proportional increase in exposure is observed with increasing dose. It is estimated that, on average, increasing the oral dose from 200 mg twice daily to 300 mg twice daily leads to a 2.5-fold increase in exposure (AUCτ) (area under the plasma concentration time curve over the 12-hour dosing interval) while increasing the intravenous dose from 3 mg/kg twice daily to 4 mg/kg twice daily produces a 2.3-fold increase in exposure. When the recommended intravenous or oral loading dose regimens are administered, plasma concentrations close to steady state are achieved within the first 24 hours of dosing. Without the loading dose, accumulation occurs during twice daily multiple dosing with steady-state plasma voriconazole concentrations being achieved by day 6 in the majority of subjects.

Absorption

Voriconazole is rapidly and almost completely absorbed following oral administration, with maximum plasma concentrations (Cmax) achieved 1 to 2 hours after dosing. The oral bioavailability of voriconazole is estimated to be 96%. Bioequivalence has been established between the 200 mg tablet and the 40 mg/mL oral suspension when administered as a 200 mg dose.

When multiple doses of voriconazole are administered with high fat meals, Cmax and AUCτ of the tablets are reduced by 34% and 24%, respectively, and Cmax and AUCτ of the suspension are reduced by 58% and 37%, respectively.

The absorption of voriconazole is not affected by changes in gastric pH.

Distribution

The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues. Plasma protein binding is estimated to be 58%.

Cerebrospinal fluid samples from eight patients in a compassionate programme showed detectable voriconazole concentrations in all patients.
**Biotransformation**

*In vitro* studies showed that voriconazole is metabolised by the hepatic cytochrome P450 isoenzymes, CYP2C19, CYP2C9 and CYP3A4.

The inter-individual variability of voriconazole pharmacokinetics is high.

*In vivo* studies indicated that CYP2C19 is significantly involved in the metabolism of voriconazole. This enzyme exhibits genetic polymorphism. For example, 15-20% of Asian populations may be expected to be poor metabolisers. For Caucasians and Blacks the prevalence of poor metabolisers is 3-5%. Studies conducted in Caucasian and Japanese healthy subjects have shown that poor metabolisers have, on average, 4-fold higher voriconazole exposure (AUC\(\tau\)) than their homozygous extensive metaboliser counterparts. Subjects who are heterozygous extensive metabolisers have on average 2-fold higher voriconazole exposure than their homozygous extensive metaboliser counterparts.

The major metabolite of voriconazole is the N-oxide, which accounts for 72% of the circulating radiolabelled metabolites in plasma. This metabolite has minimal antifungal activity and does not contribute to the overall efficacy of voriconazole.

**Elimination**

Voriconazole is eliminated via hepatic metabolism with less than 2% of the dose excreted unchanged in the urine.

After administration of a radiolabelled dose of voriconazole, approximately 80% of the radioactivity is recovered in the urine after multiple intravenous dosing and 83% in the urine after multiple oral dosing. The majority (>94%) of the total radioactivity is excreted in the first 96 hours after both oral and intravenous dosing.

The terminal half-life of voriconazole depends on dose and is approximately 6 hours at 3 mg/kg (intravenously) or 200 mg (orally). Because of non-linear pharmacokinetics, the terminal half-life is not useful in the prediction of the accumulation or elimination of voriconazole.

**Pharmacokinetic/pharmacodynamic relationship(s)**

In 10 therapeutic studies, the median for the average and maximum plasma concentrations in individual subjects across the studies was 2425 ng/mL (inter-quartile range 1193 to 4380 ng/mL) and 3742 ng/mL (inter-quartile range 2027 to 6302 ng/mL), respectively. A positive association between mean, maximum or minimum plasma voriconazole concentration and efficacy in therapeutic studies was not found.

Pharmacokinetic/pharmacodynamic (PK/PD) analyses of clinical trial data identified positive associations between plasma voriconazole concentrations and both LFT abnormalities and visual disturbances.

**Special population**

**Gender**

In an oral multiple dose study, Cmax and AUC\(\tau\) for healthy young females were 83% and 113% higher, respectively, than in healthy young males (18-45 years). In the same study, no significant differences in Cmax and AUC\(\tau\) were observed between healthy elderly males and healthy elderly females (≥65 years).
In the clinical program, no dosage adjustment was made on the basis of gender. The safety profile and plasma concentrations observed in male and female patients were similar. Therefore, no dosage adjustment based on gender is necessary.

**Elderly**

In an oral multiple dose study Cmax and AUC_τ in healthy elderly males (≥65 years) were 61% and 86% higher, respectively, than in healthy young males (18-45 years). No significant differences in Cmax and AUC_τ were observed between healthy elderly females (≥65 years) and healthy young females (18-45 years).

In the therapeutic studies no dosage adjustment was made on the basis of age. A relationship between plasma concentrations and age was observed. The safety profile of voriconazole in young and elderly patients was similar and, therefore, no dosage adjustment is necessary for the elderly.

**Paediatric population**

The recommended intravenous dose in paediatric patients is based on a population pharmacokinetic analysis of data pooled from 82 immunocompromised paediatric patients aged 2 to <12 years old who were evaluated in three pharmacokinetic studies (examining single intravenous doses of 3 and 4 mg/kg twice daily, multiple intravenous doses of 3, 4, 6 and 8 mg/kg twice daily and multiple oral suspension doses of 4 and 6 mg/kg twice daily). The majority of patients received more than one dose level with a maximum duration of dosing of 30 days. A comparison of the paediatric and adult population pharmacokinetic data indicated that in order to obtain comparable exposures to those obtained in adults following intravenous maintenance doses of 4 mg/kg twice daily, intravenous maintenance doses of 7 mg/kg twice daily are required in paediatric patients. The higher intravenous maintenance dose in paediatric patients relative to adults reflects the higher elimination capacity in paediatric patients due to a greater liver mass to body mass ratio. In order to obtain comparable exposures to those obtained in adults following intravenous maintenance doses of 3 mg/kg twice daily, intravenous maintenance doses of 4 mg/kg twice daily are required in paediatric patients. Based on the population pharmacokinetic analysis, no loading dose or dosage adjustment according to age is warranted in patients aged 2 to <12 years old.

The recommended oral dose in paediatrics is based on a population pharmacokinetic analysis data obtained from 47 immunocompromised paediatric patients aged 2 to <12 years old who were evaluated in a pharmacokinetic study examining multiple oral suspension doses of 4 to 6 mg/kg twice daily. A comparison of the paediatric and adult population pharmacokinetic data indicated that in order to obtain comparable exposures to those obtained in adults following a maintenance dose of 200 mg twice daily, the same dose of 200 mg of oral solution twice daily is required in paediatric patients, independent of body weight. In paediatric patients there is a general trend towards low bioavailability at lower body weights and high bioavailability at higher body weights (towards the extent demonstrated in adults). Based on the population pharmacokinetic analysis, no dosage adjustment according to age or weight is warranted in patients aged 2 to <12 years old at the 200 mg twice daily oral solution dosing regimen. A loading dose is not indicated in paediatric patients. Oral bioavailability may however be limited in paediatric patients with malabsorption and very low body weight for their age. In that case, intravenous voriconazole administration is recommended.
**Renal impairment**

In a single oral dose (200 mg) study in subjects with normal renal function and mild (creatinine clearance 41-60 mL/min) to severe (creatinine clearance <20 mL/min) renal impairment, the pharmacokinetics of voriconazole were not significantly affected by renal impairment. The plasma protein binding of voriconazole was similar in subjects with different degrees of renal impairment.

In patients with moderate to severe renal dysfunction (creatinine clearance < 50 mL/min), accumulation of the intravenous vehicle, SBECID, occurs. Oral voriconazole should be administered to patients with moderate to severe renal dysfunction including dialysis patients, unless an assessment of the benefit risk to the patient justifies the use of intravenous voriconazole. Serum creatinine levels should be closely monitored in these patients, and if increases occur, consideration should be given to changing to oral voriconazole therapy (see Section 4.2 Dose and method of administration).

A pharmacokinetic study in subjects with renal failure undergoing haemodialysis showed that voriconazole is dialysed with clearance of 121 mL/min. The intravenous vehicle, SBECID, is haemodialysed with clearance of 55 mL/min. A 4-hour haemodialysis session does not remove a sufficient amount of voriconazole to warrant dose adjustment.

Mean SBECID and voriconazole plasma concentrations were measured at the end of infusion on study days 3, 4 and 5 for both dialysis and normal subjects. The pharmacokinetic data indicated that exposure to SBECID was higher in dialysis subjects. There was no evidence of SBECID accumulation in normal subjects. Exposure to voriconazole was lower in the dialysis subjects. Combining the Day 3, 4 and 5 data, the ratio of the post-infusion means (dialysis/normal subjects) was 455% (95% CI: 340%, 609%) for SBECID and 50% (95% CI: 32%, 80%) for voriconazole.

**Hepatic impairment**

After a single oral dose (200 mg), AUC was 233% higher in subjects with mild to moderate hepatic cirrhosis (Child-Pugh A and B) compared with subjects with normal hepatic function. Protein binding of voriconazole was not affected by impaired hepatic function.

In a multiple oral dose study, AUCτ was similar in subjects with moderate hepatic cirrhosis (Child-Pugh B) given maintenance doses of 100 mg twice daily and subjects with normal hepatic function given 200 mg twice daily. No pharmacokinetic data are available for patients with severe hepatic cirrhosis (Child-Pugh C) (see Section 4.2 Dose and method of administration).

**5.3 Preclinical safety data**

**Genotoxicity**

Voriconazole showed no mutagenic potential in gene-mutation assays in bacterial (*Salmonella typhimurium*) and mammalian (Chinese hamster ovary) cells. While *in vitro* exposure of human lymphocytes to voriconazole produced equivocal effects on chromosomes, *in vivo* treatment of male and female mice at doses up to and including the maximum tolerated dose produced no evidence of chromosome damage as determined by the micronucleus assay.
Carcinogenicity
Carcinogenic potential was studied in mice and rats at oral doses of up to 100 mg/kg/day and 50 mg/kg/day for 24 months, respectively. Hepatocellular adenoma appeared in male and female mice at 100 mg/kg/day and in female rats at 50 mg/kg/day. There was also an increased incidence of hepatocellular carcinoma in mice at 100 mg/kg/day. Although mean plasma drug concentrations indicated there is no safety margin in humans in terms of exposure, adenoma and carcinoma (as well as non-neoplastic changes) are known to occur in rodents after chronic administration of compounds that are hepatic enzyme inducers.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Film-coated Tablets
- lactose monohydrate
- pregelatinised starch maize
- croscarmellose sodium
- povidone,
- magnesium stearate
- coating containing hypromellose, titanium dioxide, lactose monohydrate, glycerol triacetate.

Powder for Infusion
- water
- sulfobutyl betadex sodium (SBEC).

Powder for Oral Suspension
- sucrose
- anhydrous silica colloidal
- titanium dioxide
- xanthan gum
- sodium citrate dihydrate
- sodium benzoate
- anhydrous citric acid
- natural orange flavour.

6.2 Incompatibilities

Intravenous administration

Blood products and electrolyte supplementation
Voriconazole must not be infused concomitantly with any blood product or any short-term infusion of concentrated solution of electrolytes, even if the two infusions are running in separate lines. Electrolyte disturbances such as hypokalaemia, hypomagnesaemia and hypocalcaemia should be corrected prior to initiation of voriconazole therapy (see Section 4.4 Special warnings and precautions for use, Cardiovascular).
**Intravenous solutions containing (non-concentrated) electrolytes**

Voriconazole can be infused at the same time as other intravenous solutions containing (non-concentrated) electrolytes, but must be infused through a separate line.

**Total parenteral nutrition (TPN)**

Voriconazole can be infused at the same time as total parenteral nutrition, but must be infused in a separate line. If infused through a multiple-lumen catheter, TPN needs to be administered using a different port from the one used for voriconazole.

Voriconazole must not be diluted with 4.2% sodium bicarbonate infusion. Compatibility with other concentrations is unknown.

Vfend Powder for Infusion must not be mixed with other medicinal products except those mentioned under Section 6.6 Special precautions for disposal and other handling, Reconstitution instructions - Powder for Infusion.

Vfend Powder for Oral Suspension must not be mixed with other medicinal products except those mentioned in Section 6.6 Special precautions for disposal and other handling, Reconstitution instructions - Powder for Oral Suspension.

**6.3 Shelf life**

Film coated Tablets: 36 months, Stored below 30°C.

Powder for Oral Suspension: 24 months, Stored at 2° to 8°C (Refrigerate, do not freeze). Store reconstituted suspension below 30°C. Discard suspension 14 days after reconstitution.

Powder for Infusion: 36 months.

Vfend Powder for Infusion contains no antimicrobial agent. From a microbiological point of view, once reconstituted, the product must be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C (in a refrigerator), unless reconstitution has taken place in controlled and validated aseptic conditions.

Chemical and physical in-use stability has been demonstrated for 24 hours at 2°C to 8°C.

**6.4 Special precautions for storage**

Film coated Tablets: This medicinal product does not require any special storage conditions.

Powder for Oral Suspension and Powder for Infusion: For storage conditions after reconstitution of the product, see section 6.3 Shelf life.

**6.5 Nature and contents of container**

Vfend film coated Tablets are supplied in PVC/Aluminium blisters of 2, 10, 14, 20, 28, 30, 50, 56 and 100 tablets in cartons.
Vfend Powder for Oral Suspension is supplied in a 100 mL HDPE bottle. A measuring cup, 5 mL syringe dispenser and a press-in bottle adaptor are also provided.

Vfend Powder for Infusion is supplied in Type 1 clear glass 30 mL single use vials. Pack of 1 vial.

Not all pack sizes may be marketed.

**6.6 Special precautions for disposal and other handling**

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

**Reconstitution instructions - Powder for Oral Suspension**

1. Tap the bottle to release the powder.

2. Add a total of 46 mL of distilled water to the bottle: Measure 23 mL of water by filling the measuring cup to the top of the marked line. Add the water to the bottle. Using the cup, measure another 23 mL of water and add this to the bottle. Replace the cap and ensure it is firmly closed.

3. Shake the closed bottle vigorously for about 1 minute.

4. Remove child-resistant cap. Press bottle adaptor into the neck of the bottle and replace cap.

Reconstituted Vfend Powder for Oral Suspension should be shaken well before use.

Vfend Powder for Oral Suspension should be administered using the syringe provided in the pack.

Vfend Powder for Oral Suspension should not be mixed with any other medication. It is not intended that the reconstituted suspension be further diluted with water or other vehicles.

**Reconstitution instructions - Powder for Infusion**

The powder should be reconstituted with 19 mL of Water for Injections. Shake thoroughly to give a clear concentrate containing 10 mg/mL of voriconazole and an extractable volume of 20 mL. It is recommended that a standard 20 mL (non-automated) syringe be used to ensure that the exact amount (19.0 mL) of Water for Injections is dispensed. Discard the vial if a vacuum does not pull the diluent into the vial.

For administration, the required volume of the reconstituted concentrate is added to a recommended compatible infusion solution (detailed below) to obtain a final solution containing voriconazole at a concentration between 0.5 mg/mL and 5 mg/mL. It is recommended that Vfend should be administered at a maximum rate of 3 mg/kg per hour over 1 to 2 hours and not as a bolus injection.

The reconstituted solution can be diluted with:

- 0.9% Sodium chloride intravenous infusion
• Compound sodium lactate intravenous infusion
• 5% Glucose and compound sodium lactate intravenous infusion
• 5% Glucose and 0.45% sodium chloride intravenous infusion
• 5% Glucose intravenous infusion
• 5% Glucose in 20 mEq potassium chloride intravenous infusion
• 0.45% Sodium chloride intravenous infusion
• 5% Glucose and 0.9% sodium chloride intravenous infusion.

The compatibility of Vfend Powder for Infusion with diluents other than those described above is unknown (see Section 6.2 Incompatibilities).

7. MEDICINE SCHEDULE

Prescription medicine.

8. SPONSOR

Pfizer New Zealand Limited
P O Box 3998
Auckland, New Zealand.

Toll Free Number: 0800 736 363.

9. DATE OF FIRST APPROVAL

Film coated Tablets and Powder for Infusion: 28 November 2002.


10. DATE OF REVISION OF THE TEXT

09 April 2019.

Summary table of changes (09 April 2019)

<table>
<thead>
<tr>
<th>Section changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.4, 4.8</td>
<td>Addition of safety warning and AE, DRESS.</td>
</tr>
</tbody>
</table>